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Abstract 
Background: Dual diagnosis covers a broad spectrum of mental health and substance misuse 
conditions occurring concurrently (NICE, 2016). Its manifestation is complex and as such the 
disorder is recognized as influencing adherence to prescribed medication, service engagement 
and has a worse prognosis than substance use and mental health conditions occurring 
independently. 
Aims: To determine the effectiveness of psycho-educational group therapy on a sample of 
dual diagnosis patients. 
Methods: Patients who met the DSM-IV Axis 1 criteria for serious mental illness and current 
substance misuse were approached to take part in a psycho-educational programme. Those 
who consented were assessed at baseline and end-point using measures of psychiatric 
symptomology, psychological well-being and substance use patterns with the following 
scales; Brief Psychiatric Rating Scale (BPRS), Hospital Anxiety and Depression Rating Scale 
(HADS), Maudsley Addiction Profile Scale (MAPS) and the Warwick and Edinburgh Mental 
Well-being Scale (WEMWBS).  
Results: Fifty-one patients completed the programme whilst 29 dropped out after initial 
assessment. Between baseline and follow-up there was a decline in the number of participants 
using alcohol, cannabis, cocaine, amphetamine, illicit benzodiazepines and methadone. 
However, the number of participants using heroin remained constant. The mean amount of 
substances used did not reduce over the study period except in the case of alcohol. Overall 
improvements in symptomology and psychological well-being were observed. 
Discussion: Mental health services should focus on integrated approaches via multimodal 
treatment interventions that encapsulate harm reduction and educational initiatives: Despite 
the modest sample, the findings have emphasised the importance of a broad range of 
treatment approaches delivered within a unitary delivery system.   
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Introduction  
 
The term dual diagnosis covers a broad spectrum of mental health and substance misuse 
conditions occurring concurrently (NICE, 2016). The manifestation of these two conditions is 
often varied, complex and can modify over time because of changes in the use of licit and 
illicit substances which impact on symptom profile. The disorder is also recognized as 
influencing adherence to prescribed medication, service engagement and has a worse 
prognosis than substance use and mental health conditions occurring independently (Bellack, 
Bennett, Gearon, Brown, & Yang, 2006). 
 
The epidemiological nature of dual diagnosis is multifaceted in which diagnostic complexity 
is viewed as the expectation rather than the exception within clinical practice (C. T. Jackson, 
Covell, Drake, & Essock, 2007; Minkoff, 2013). Substance misuse among psychiatric 
spectrum disorders is widespread (NICE, 2016). Current estimates in the United Kingdom 
(UK) suggest that a third of patients with Serious Mental Illness (SMI) have an active 
Substance Use Disorder (SUD) encompassing an expansive range of psychopathology; 
including schizophrenia, mood, dissociative and personality syndromes (Health, 2006). 
Engaging the dual diagnosis patient population in therapeutic intervention presents a number 
of complex challenges for mental health services (Cochrane, 2008; Derry, 200). Studies 
indicate that treatment dropout rates are high (Bellack et al., 2006; Gobbart, 2013), with 
contributing factors including chaotic and complex lifestyles (Barrowclough et al., 2007). In 
addition, there is often a decline in mental and physical functioning due to substance misuse 
exacerbating psychological and emotional conditions. This, in turn, leads to increasingly poor 
levels of functioning and disengagement with services (Minkoff & Cline, 2005). The clinical 
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challenges therefore require a flexible and pragmatic treatment approach that meets the 
multifarious demands of this patient population (NICE, 2011a, 2011b, 2014).  
 
Psychotherapeutic models of practice incorporate a number of treatment methods including 
motivational enhancement therapy, harm-minimisation and group psychotherapy. These can 
be deployed alongside more traditional and stronger evidence based methods such as 
Cognitive Behavioural Therapy (CBT) and pharmacotherapy, which is regarded as 
operationally efficacious for individuals with a range of co-morbid conditions (NICE, 2014). 
Drug prevention and harm reduction models of care, which are embedded in group 
psychotherapy, are acknowledged as being beneficial in supporting a holistic and integrated 
approach to mainstream service provision, which promotes an individual’s mental and 
physical well-being (Walker et al, 2013). There are a number of service models delivered in a 
variety of service configurations; however, two approaches, which currently influence 
clinical practice, are the parallel and sequential models (NICE, 2016). The former is where an 
individual is treated independently by a mental health or substance misuse service. The 
sequential model infers primacy of either the mental health or substance misuse problem, 
thereby treating one before the other. The program, which forms the basis of this evaluation, 
is novel and distinct from parallel and sequential models because it combines both mental 
health and substance misuse treatment provided by the same team of clinicians at the same 
time. The potential advantages of such an integrated and holistic approach are that both 
elements of the dual problems are given due attention in one setting. Psycho-educational 
group therapy programs grounded in multimodal integrated treatment approaches affords 
participants the capacity to change patterns of substance use and their concomitant effects on 
mental health by addressing both problems simultaneously (Bellack et al., 2006; Gobbart, 
2013; Sibitz, Amering, Gössler, Unger, & Katschnig, 2007; Weiss et al., 2007). Therapeutic 
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group settings comprise a range of implicit protective factors that are considered beneficial in 
reducing an array of environmental and situational stressors (e.g. stigma, victimisation and 
prejudice), often encountered by people with mental health and substance misuse conditions 
(Tay, 2011). Therefore, participation in group psychotherapy provides a series of positive 
opportunities for participants to experience durable social support structures that augment 
therapeutic approaches such as harm reduction and health education, supporting the effective 
management of individuals with complex health care needs. 
 
Psychoeducational therapy contributes to a broader treatment perspective by blending 
therapeutic approaches and intervention techniques alongside standard treatment provision. 
This provides individuals the opportunity to enhance their understanding of their complex 
clinical presentations and the potential for sustaining long-term beneficial change within a 
supportive social milieu (Dixon, Holoshitz, & Nossel, 2016). The aim of the study was to 
examine the efficacy of psychoeducational treatment provision in a dual diagnosis 
population. 
 
Methods 
 
Psycho-Educational Group (PEG) Therapy for Dual Diagnosis 
 
The PEG treatment program was developed as a partnership outreach project between state 
and non-state services working with dual diagnosis patients. It provides individuals with an 
opportunity to access and engage in an integrated treatment intervention, which recognises 
the complex needs of this population.  The program is based around psycho-educational, 
harm reduction, motivational and goal setting techniques which were adapted from a 
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recovery based dual diagnosis treatment manual (Derry, 2008). Inclusion in the program was 
based on levels of motivation and engagement in the treatment process as measured by the 
Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES) (Derry, 2008; 
Miller & Tonigan, 1996). The PEG therapy model aimed to increase participants’ capacity to 
change their pattern of substance misuse and to provide relevant information concerning 
aspects of mental and physical well-being. It introduced the concepts of relapse prevention 
and harm reduction, identifying common threats to maintaining aspects of clinical and 
personal recovery (See Table 1). The treatment model subsequently supported transformative 
skill building via threshold learning processes, for example assertiveness training to modify 
maladaptive behaviours. This assisted individuals to maintain a restorative focus on their 
psychopathology, supported by effective socialisation processes within a therapeutic 
framework (Wertshc, 1986). Treatment comprised of weekly, two-hour sessions during 
afternoon periods, with each program lasting 10 weeks per group. The maximum size of each 
group was set at 12 participants to ensure it was large enough to enable all involved to engage 
effectively (Morgan & Carson, 2009). Once the group program commenced, it was closed to 
new members and those who wanted to join were put on a waiting list. A total of eight 
programs were completed during the 18-month period of the evaluation. In order to generate 
a sense of ownership and control over the group, specific ground rules were agreed e.g. 
confidentiality, respect for fellow group members and punctuality. These group boundaries 
were decided collectively amongst participants as far as was practical and were reinforced at 
the commencement of each group session. Group sessions were led by four qualified Health 
Care Professionals (HCPs) trained in facilitating group therapy. They all had received 
additional Motivational Enhancement (ME) training prior to the study commencing. Fidelity 
of sessions was measured by regular debrief with all facilitators post group sessions and 
evaluation of facilitator performance and feedback post-group program. 
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Table 1. Psycho-Educational Group (PEG) Therapy Session Outline 
Week Session Content 
1 1 Introduction and PEG boundaries. 
  2 Choice and empowerment. 
2 1 Motivation to change. 
  2 Overcoming barriers to change. 
3 1 Understanding my substance misuse. 
  2 How I use substances to affect my mood/behaviour. 
4 1 Do substances affect my mental health? 
  2 Substance use and mental health relapse. 
5 1 Relapse prevention. 
  2 Developing skills. 
6 1 Relapse prevention planning. 
  2 Coping with cravings. 
7 1 Coping with emotions. 
  2 Coping with symptoms and side effects. 
8 1 Getting support. 
  2 Skills practice. 
9 1 Changing lifestyle and moving on. 
  2 Skills role-play. 
10 1 
2 
Relapse prevention and planning revisited. 
Group evaluation and provision of education pack. 
   
 Note. PEG = Psycho-Educational Group. 
 
Recruitment to the PEG Program and Evaluation 
Recruitment to the PEG evaluation initiated after participants met the inclusion criteria of 
working-age adults (ages 18-65) who met the DSM-IV Axis 1 criteria for Serious Mental 
Illness (SMI) and current substance misuse. All participants were assessed for appropriate 
mental health clustering by their medical consultant and care coordinator. Letters of 
invitation were forwarded to potential participants to participate in the assessment interview. 
The information obtained at the interview was primarily to ascertain whether a potential 
participant met the inclusion criteria, wanted to engage in the study and was able to provide 
informed consent. Copies of the patient information sheet were provided to assist potential 
participants to make an informed decision regarding participation in the study. A free post-
return envelope was provided in order that potential participants could return the signed 
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consent form after the assessment interview.  Once consent was obtained participants were 
given a two week cooling off period in which to re-consider participation in accordance with 
the guidelines stipulated in the Cochrane handbook for undertaking research in health care 
settings (Cochrane, 2008). Patients were recruited from a variety of community mental health 
sources, e.g., Assertive Outreach Teams and Early Intervention Teams. All participants were 
able to withdraw from the research process at any stage by contacting a member of the 
research team. The study was granted ethical approval from the National Health Service 
Ethics Committee in July 2009.  
 
Over an 18-month period, 80 patients agreed to participate in both the program and 
evaluation. However, subsequent to their consent and initial engagement in the program, 29 
patients dropped out leaving a sample of 51 to complete both the PEG program and 
evaluation. The most common reasons for withdrawal were lack of transport access to allow 
attendance at PEG sessions, conflict of group timings with work schedules, and treatment and 
non-treatment side effects.   
 
Assessment Measures 
There were four assessment measures used in this study: 
i) The Hospital Anxiety and Depression Rating Scale (HADS) (Zigmond & Snaith, 
1983) is a 14 item self-assessment scale designed to detect states of depression, 
anxiety and emotional distress. Items are scored from 0-3, the higher the score 
indicating worse symptomatology. Symptom frequency scores for each subscale 
(anxiety and depression) range from 0-21, with scores categorised as normal (0-7), 
mild (8-10), moderate (11-14), and severe (15-21). Scores for the entire scale 
(emotional distress) range from 0-42, with higher scores indicating additional 
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distress. The scale is shown to have sound reliability and validity (McDowell, 
2006), and has previously been used in dual diagnosis research (Manning et al., 
2009).  
ii) The Brief Psychiatric Rating Scale (BPRS) (Overall & Gorham, 1962) is a 
clinician-rated tool designed to assess the severity of a wide range of mental 
health symptoms associated with psychotic disorders including positive, negative 
and affective symptoms. The 24 item version of this scale was used in the current 
study (Lukoff, Liberman, & Nuechterlein, 1986). Each item is scored on a 0-7 
Likert scale ranging from ‘not present’ to ‘extremely severe’ and provides a 
continuous total score (0-168).   Principal component analyses have indicated that 
the scale items can be categorised according to Positive and Negative symptoms 
as well as Mania and Depression (Ventura, Nuechterlein, Subotnik, Gutkind, & 
Gilbert, 2000), whilst other authors have identified Disorientation as a distinct 
component (Dingemans, Linszen, Lenior, & Smeets, 1995). The measure has 
sound psychometric properties (Zigmond & Snaith, 1983), and has been 
previously used in a similar population group (Baker et al., 2006). 
iii) The Warwick-Edinburgh Mental Well-being Scale (WEMWBS) (Tennant et al., 
2007) is a measure of mental well-being focusing entirely on positive aspects of 
mental health. The scale consists of 14 items on a five-point scale ranging from 1-
5 with the range of scores between 14 and 70.  A higher score indicates a higher 
level of mental well-being. The scale demonstrates good properties of reliability 
and validity, and has been used in a dual diagnosis population previously (Ujhelyi 
et al., 2016).  
iv) The Maudsley Addiction Profile (MAP) (Tennant et al., 2007) is a brief multi-
dimensional instrument designed to assess longitudinal treatment outcomes of 
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individuals with substance misuse problems. The MAP presents a snapshot of an 
individual over a 30-day interval, comprising areas of health risk and social 
functioning. It is used extensively in addiction treatment outcome research and can 
be used to provide a comprehensive measure of an individual’s current substance 
misuse. Higher scores indicate elevated levels of problem severity. The instrument 
demonstrates good psychometric properties (Barbieri, 2003).  
 
Tools were administered pre-intervention as part of the induction process, post-intervention 
data were collected during the final week of the PEG.  
 
Descriptive and Inferential Statistics  
Analyses were completed using the Statistical Package for the Social Sciences for Windows 
(SPSS-version 19) (Gray & Kinnear, 2012). Descriptive statistics were used to show 
frequency and percentage data relating to demographic and diagnostic characteristics, 
proportion of patients using substances, mean amounts of substances used and mean 
symptom scores.  Independent samples t-tests were used to compare those who completed the 
study (Completers) with those who did not (Dropouts) on measures of; age, dosage of 
prescribed medication, amount used of non-prescribed substances, mental health and well-
being. Paired samples t-tests were used to compare pre and post-intervention scores for the 
completer group on the amount used of non-prescribed substances and on all measures of 
mental health and well-being. 
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Results 
Our study sample comprised 51 patients who completed the PEG program, whilst another 29 
patients failed to complete the intervention. Within psychiatric research, it is important to 
study the demographic and clinical characteristics of the dropout group, as well as the 
completer group because this tells us how representative the completing sample are of the 
wider population sample under investigation. It can also provide important information as to 
the suitability of the intervention for all patients within the target population.  
 
Demographic and Diagnostic Characteristics: Completers vs Dropouts 
As can be seen in Table 2, age and gender distribution were similar between dropouts and 
completers. Within ICD10 Primary Diagnosis, there were some differences between groups, 
with a much larger representation of F10-F19 disorders (disorder due to psychoactive 
substance use)  for the completing group, whilst the dropout group had their majority 
representation within the F20-F29 classification (schizophrenia and delusional disorders).  
For ICD 10 Secondary Diagnosis, the completer group had their highest prevalence rates 
within two categories, F10-F19 (disorder due to psychoactive substance use) and F40-F48 
(neurotic stress related and somatoform disorders). In contrast, the dropout group had their 
highest representation within the schizophrenia and delusional disorder group.  
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Table 2. Comparison of demographic and diagnostic characteristics between patients completing the 
study and those who dropped out.   
Demographic and Diagnostic Characteristics Completers 
(n = 51) 
Drop-outs 
(n = 29) 
Age – mean (SD)      34.51 (8.8) 38.03 (9.0)  
Gender – (male: female, %)  54.9: 45.1 65.6: 34.5 
 ICD 10 Primary Diagnosis (%)  
Mental Behaviour Disorder Due to Psychoactive Substance Use (F10-F19) 58.8 3.4 
Schizophrenia and Delusional Disorders (F20-F29) 23.5 55.2 
Mood Affective Disorders (F30-F39) 9.8 34.5 
Neurotic Stress Related and Somatoform Disorders (F40-F48) 7.8 6.9 
ICD 10 Secondary Diagnosis (%)*  
    Mental Behaviour Disorder Due to Psychoactive Substance Use (F10-F19) 35.3 3.4 
Schizophrenia and Delusional Disorders (F20-F29) 11.8 55.2 
Mood Affective Disorders (F30-F39) 15.7 34.5 
Neurotic Stress Related and Somatoform Disorders (F40-F48) 35.3 6.9 
ICD 10 Tertiary Diagnosis (%)  
Mental Behaviour Disorder Due to Psychoactive Substance Use (F10-F19) 5.9 - 
Schizophrenia and Delusional Disorders (F20-F29) - - 
Mood Affective Disorders (F30-F39) - - 
Neurotic Stress Related and Somatoform Disorders (F40-F48) 19.6 6.9 
Not Used 74.5 93.1 
Note. * ICD 10 Secondary Diagnosis Data missing for 2 participants in the completer group. 
 
 
Prescribed Medication: Completers vs Dropouts 
A higher percentage of completers were prescribed opiates (9 vs. 6%), benzodiazepines (7 vs. 
6%), antidepressants (60 vs. 51%) and antipsychotics (20 vs. 17%) than dropouts. However, 
there was an observable trend for the dropout group to be prescribed higher doses of all 
medications except antidepressants, although this difference did not reach statistical 
significance for any medication (p > .05).  
 
Substance Use: Completers vs Dropouts 
The most frequently used substance was alcohol across both groups and a similar percentage 
of completers and dropouts had used this substance in the 30 days prior to the study (Table 
3).  An independent samples t-test comparing the amount of alcohol used between groups 
showed that the completers consumed more units of alcohol than the dropouts (24.70 vs. 
16.58 units; t (50) = 3.22, p = .002).   The second most frequently used substance was 
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cannabis with a higher percentage of completers using this substance compared to dropouts. 
However, the number of ounces of cannabis used per day did not differ between groups (.308 
vs. .206 ounces; t (34) = 0.82, p = .41).  The third most common substance used across both 
groups was heroin, with a lower percentage of completers using this substance compared to 
dropouts. The number of grams of heroin used per day did not differ between groups (.285 vs 
.343 grams; t (13) = - 0.97, p = .34).   Although the number of users of illicit methadone, 
illicit benzodiazepines, cocaine and amphetamine was low within both groups, more 
completers compared to dropouts used all substances. The low subject numbers do not permit 
reliable statistical analyses between these groups on the amount of these substances used.  
 
Table 3. Comparison of substance use between completers and drop-outs  
 
Substance Participants Using Substance 
N (%) 
†Amount used 
Mean (SD) 
 Completers Drop-outs Completers Drop-outs 
Alcohol  33 (64.7) 19 (65.5) 24.70 (10.24) 16.58 (5.05)* 
Heroin  7 (13.7) 8 (27.6) 0.28 (0.09) 0.34 (0.12) 
Illicit Methadone 2 (3.9) 1 (3.4) 10.00 (0) 10.00 (-) 
Illicit Benzodiazepines 5 (9.8) 4 (13.8) 10.00 (5.00) 12.40 (5.00) 
Cocaine 9 (17.6) 4 (13.8) Missing Data 
Amphetamine 5 (9.8) 2 (6.9) 0.75 (0.77) 0.37 (0.17) 
Cannabis 25 (49) 11 (37.9) 0.30 (0.37) 0.20 (026) 
Note. SD = Standard deviation.  
†Units of Measurement: Alcohol intake was measured in units, methadone and illicit benzodiazepines in mg, cocaine 
and amphetamine in grams and cannabis in ounces 
*The difference in amount of alcohol used between completers and dropouts was statistically significant (p < .05) 
 
Mental Health and Well-Being Measures: Completers vs Dropouts 
In comparison to the completer group, the dropouts exhibited more severe negative, 
depressive, manic and disorientation symptoms according to the BPRS (p < .05). However, 
there were no statistically significant differences between groups on BPRS positive 
symptoms, nor on the HADS or WEMWBS. See table 4.   
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Table 4. Comparison of scores between completers and dropouts on mental health and well-being 
measures  
 
Measure 
 
Completers 
Mean (SD) 
n = 51 
Drop-outs 
Mean (SD) 
n = 29 
Difference 
 
t (df) P (two 
tailed) 
BPRS Positive Symptoms 13.59 (4.91) 13.66 (4.27) 0.07 -0.06 (78) .951 
†BPRS Negative Symptoms 8.96 (2.58) 11.34 (3.23) 2.38 -3.29 (78) .001* 
BPRS Depression 15.39 (3.00) 17.31 (3.08) 1.92 -2.72 (78) .008* 
BPRS Mania 11.10 (3.62) 12.86 (4.02) 1.76 -2.01 (78) .048* 
BPRS Disorientation 3.61 (1.73) 4.45 (1.66) 0.84 -2.11 (78) .037* 
HADS - Anxiety 6.65 (3.86) 5.24 (2.43) -1.41 1.76 (78) .081 
HADS-Depression 8.18 (3.28) 7.45 (2.48) -0.73 1.03 (78) .303 
HADS -Total 14.82 (6.85) 12.69 (4.23) -2.13 1.51 (78) .133 
‡WEMBWS 35.96 (5.25) 37.38 (3.66) 1.42 -1.28 (78) .202 
Note. BPRS = Brief Psychiatric Rating Scale; HADS = Hospital Anxiety and Depression Rating Scale; 
WEMWBS = Warwick Edinburgh Mental Well Being Scale; SD = Standard deviation. 
Note. † reduced sample n = 50 
‡Higher scores on the WEMBWS indicate improved mental well-being whilst lower scores on all other measures indicate 
improved mental health. 
*p < .05 
 
 
Completer Group: Comparison on all variables pre and post-intervention 
 
Prescribed Medication: Completers Pre and Post-Intervention   
The most commonly prescribed medications for patients at the start of the study were 
antidepressants (n = 31) and antipsychotics (n = 20) although five patients were prescribed 
opiates, four patients benzodiazepines and one patient lithium. The only change to this 
pattern at the end of the intervention was that one patient fewer was taking a benzodiazepine. 
In terms of medication dosage, this remained stable for all medications except that there was 
a slight decrease in the prescribed daily amount of antidepressant which approached 
statistical significance (31.61 mg vs. 28.39 mg; t (30) = 1.77, p = .086).  
 
Substance Use: Completers Pre and Post-Intervention   
The most commonly used substances both at pre-intervention and post-intervention were 
alcohol and cannabis, although there was a slight decline in the number of participants using 
each substance at post-intervention compared to pre-intervention (alcohol 33 vs. 30; cannabis 
25 vs. 24). In terms of the other substances, there was a decline in the number of patients 
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using cocaine (9 vs. 4), illicit benzodiazepines (5 vs. 3) amphetamine (5 vs. 2) and illicit 
methadone (2 vs. 0). However, the number of participants using heroin remained constant 
over the study period (7 vs.7).  
 
The amount of each illicit substance used per day remained stable over the study period 
except for alcohol where there was a mean decline of five units per day, which was 
statistically significant. A decline was also observed in the dosage of benzodiazepines, which 
approached statistical significance. See Table 5.     
 
Table 5. Mean amount of substances used per day pre and post intervention (n = 50 for alcohol and 
cocaine but 51 for other substances) 
 
Substance 
 
Pre-Intervention 
amount 
Mean (SD) 
Post- Intervention 
amount 
Mean (SD) 
Mean Change 
Score 
(SD) 
t (df) P (two tailed) 
Alcohol 15.70 (14.4) 10.70 (11.28) - 5.00 (8.20) 4.3 (49)    0.00* 
Heroin .0392 (.10) .0392 (.10) 0 (0.5) 0.0 (50) 1.00 
Illicit  Methadone .39 (1.96) .00 -0.39 (1.96) 1.42 (50) 0.15 
Illicit 
benzodiazepines 
.98 (3.3) .49 (2.06) -0.49 (1.80) 1.94 (50) .058 
Cocaine .08 (.29) .02 (.06) -0.06 (.28) 1.47 (49) 0.14 
Amphetamine .0735 (.31) .0098 (.04) -0.06 (.31) 1.46 (50) 0.15 
Cannabis .1513 (.30) .1422 (.30) -0.00 (.07) 0.03 (50) 0.38 
Note. SD = Standard deviation. Units of Measurement: Alcohol intake was measured in units, methadone and 
illicit benzodiazepines in mg, cocaine and amphetamine in grams and cannabis in ounces 
*p < .001 
 
Mental Health and Well-Being Measures: Completers Pre and Post-Intervention   
On all measures of psychiatric symptomology and mental well-being, there were statistically 
significant improvements over the study period. See Table 6.  
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Table 6. Mean scores on mental health and well-being measures pre and post intervention (n = 51 for 
all measures except BPRS negative symptoms where n = 50) 
 
Measure 
 
Pre Intervention 
(SD) 
Post-Intervention 
(SD) 
Mean Change 
Score 
(SD) 
t (df) P (two 
tailed) 
BPRS – Positive 
Symptoms 
13.59 (4.91) 10.53 (3.39) -3.05 (5.54) 3.93 (50)  
 
 
 
All p values 
<.001 
 
BPRS – Negative 
Symptoms 
8.96 (2.58) 7.10 (1.87) -1.86 (2.64) 4.98 (49) 
BPRS Depression 15.39 (3.00) 12.51 (2.70) -2.88 (3.80) 5.40 (50) 
BPRS Mania 11.10 (3.62) 8.92 (2.20) -2.17 (3.57) 4.35 (50) 
BPRS Disorientation 3.61 (1.73) 2.65 (1.18) -0.96 (1.83) 3.74 (50) 
HADS - Anxiety 6.65 (3.86) 4.92 (3.27) -1.72 (2.99) 4.11 (50) 
HADS-Depression 8.18 (3.28) 6.71 (2.33) -1.47 (2.31) 4.53 (50) 
HADS -Total 14.82 (6.85) 11.63 (5.35) -3.19 (4.83) 4.72 (50) 
WEMBWS* 35.96 (5.25) 39.65 (4.36) 3.69 (4.87) -5.39 (50) 
Note. BPRS = Brief Psychiatric Rating Scale; HADS = Hospital Anxiety and Depression Rating Scale; 
WEMWBS = Warwick Edinburgh Mental Well Being Scale; SD = Standard deviation.  
*Higher scores on the WEMWBS indicate improved mental well-being whilst lower scores on all other measures indicate 
improved mental health. 
 
 
Discussion 
The aim of this study was to evaluate the effectiveness of a Psychoeducational Group (PEG) 
therapy program for individuals with dual diagnosis.  The main findings were that completion 
of the PEG program resulted in significant improvements on all symptom and psychological 
well-being measures. Furthermore, the number of participants using all substances declined 
except in the case of heroin. The amount of alcohol used also declined over the study period. 
These findings are consistent with other research suggesting therapeutic programs are 
effective with dual-diagnosis populations (Bellack, Barnett, & Gearon, 2007; Gobbart, 2013).  
With regard to heroin, the use of this substance appears to be resistant to psychoeducational 
intervention. Despite the decline in the number of participants using all other substances, the 
use of alcohol and cannabis was still prevalent at the end of the intervention. This tendency 
for some of the group to ‘self-medicate’ whilst in treatment reinforces the clinical imperative 
of monitoring ongoing substance-use when treating individuals with dual-diagnoses.  This 
might be particularly important for the most widely used substances at pre and post-
intervention; alcohol and cannabis (Barnett et al., 2007; K. M. Jackson, Sher, & Schulenberg, 
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2008). Both substances are often associated with persistent and consistent levels of relapse 
and sustained substance misuse within mental health services, (Zammit et al., 2008). Indeed, 
Nutt (Nutt, King, & Nichols, 2013) states that the use of cannabis is a major risk factor in 
individuals with a predisposition to developing psychotic disorders who may react negatively 
to stressful life events by misusing substances. This may cause individuals to develop 
unhealthy and maladaptive management techniques, resulting in higher incidences of stress 
and social vulnerability. Nevertheless, these findings do suggest psychoeducation can have 
positive effects on mental health and psychological well-being, as well as on substance 
misuse patterns.  
 
Our comparison of the completer group and the dropout group at baseline revealed that the 
dropouts had more severe mental health symptoms on most of the dimensions of the BPRS, 
but no differences were observed on the HADS nor our measure of psychological well-being.  
This is perhaps not surprising given that the majority of the dropouts were diagnosed with 
schizophrenia and delusional disorders, symptoms that the BPRS is particularly sensitive to.  
These findings suggest that some of the features of schizophrenia and delusional disorders 
may act as a barrier to sustained participation in a psychoeducational program. In terms of 
substance use differences between these groups, the completer group were more likely than 
the dropouts to use cannabis and more units of alcohol. In contrast, the dropout group had a 
higher percentage of patients using illicit benzodiazepines and heroin than the completers. 
The dependency liability of these drugs might have contributed to patients disengaging from 
the program, and it is useful to have identified the substances, which appear to hinder 
attempts at therapeutic intervention. To understand more about why participants in these 
groups dropped out, further research could be undertaken to seek their views to help inform 
future practice and strategies for treatment compliance.   
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The integration of services to meet the complex needs of individuals with serious mental 
health problems who use alcohol and drugs represents an ongoing challenge for clinical care. 
Participation of dual diagnosis patients in a 10-week PEG therapy program was successful in 
improving outcome in terms of symptom functioning, psychological well-being and changes 
in substance misuse.  However, the findings derived from the analyses should be viewed with 
caution due to the absence of a control group who did not take part in the intervention but 
who nonetheless were assessed at the same time intervals as the completer group. In addition, 
a follow up of the dropout group would also have useful, as well as a longer-term assessment 
of the completer group to see if the positive effects of the intervention had been sustained. 
Integrated treatment for dual diagnoses should be consistent and comprehensive, where both 
the mental illness and the substance use disorder are treated simultaneously in a coordinated 
manner with interventions that address both illnesses (Drake, O’Neil, & Wallach, 2012). 
Ideally, in this model of care, health care professionals working in one clinical setting provide 
appropriate treatment for both disorders simultaneously. The current dual diagnosis program 
will continue to develop and expand with active service user involvement in that planning 
process. 
 
Acknowledgements 
 
Many thanks to all the patients who participated in the psychoeducational therapy 
programme. 
 
Disclosures 
 
There are no conflicts of interest. This research did not receive any specific grant from 
funding agencies in the public, commercial, or not-for-profit sectors. None of the authors 
received any financial incentive for this study.  
Psychoeducational therapy in dual diagnosis 
19 
 
References  
Baker, A., Bucci, S., Lewin, T. J., Kay-Lambkin, F., Constable, P. M., & Carr, V. J. (2006).  
Cognitive–behavioural therapy for substance use disorders in people with psychotic 
disorders. The British Journal of Psychiatry, 188(5), 439-448.  
Barbieri, H. T. (2003). Evaluation of the Maudsley Addiction Profile (MAP) for use with an  
American substance abuse population. Philadelphia: College of Osteopathic 
Medicine. 
Barnett, J. H., Werners, U., Secher, S. M., Hill, K. E., Brazil, R., Masson, K. I., & Jones, P. 
B. (2007). Substance use in a population-based clinic sample of people with first-
episode psychosis. British Journal of Psychiatry, 190, 515-520.  
Barrowclough, C., Haddock, G., Lowens, I., Allott, R., Earnshaw, P., Fitzsimmons, M., &  
Nothard, S. (2007). Psychosis and drug and alcohol problems. In A. Baker & R. 
Velleman (Eds.), Clinical handbook of co-existing mental health and drug and 
alcohol problems (pp. 241-266). London: Routledge. 
Bellack, A. S., Barnett, M., & Gearon, J. (2007). Behavioural treatments for substance abuse  
in people with serious and persistent mental illness: A handbook for mental health 
professionals. New York: Routledge. 
Bellack, A. S., Bennett, M. E., Gearon, J. S., Brown, C. H., & Yang, Y. (2006). A 
randomized clinical trial of a new behavioral treatment for drug abuse in people with 
severe and persistent mental illness. Archives of General Psychiatry, 63(4), 426-432. 
doi:10.1001/archpsyc.63.4.426 
Cochrane. (2008). Handbook for systematic reviews of interventions. London: Wiley- 
Blackwell. 
Department of Health (2006). Dual Diagnosis in mental health inpatient and day hospital 
settings. Guidance on the assessment and management of patients in mental health 
Psychoeducational therapy in dual diagnosis 
20 
 
inpatient and day hospital settings who have mental ill health and substance use 
problems. Department of Health, London. 
Derry, A. (2008). The clinical response to substance use problems in forensic mental health  
services. British Journal of Forensic Practice, 10, 20-23.  
Dingemans, P. M. A. J., Linszen, D. H., Lenior, M. E., & Smeets, R. M. W. (1995). 
Component structure of the expanded Brief Psychiatric Rating scale (BPRS-E). 
Psychopharmacology, 122(3), 263-267. doi:10.1007/BF02246547 
Dixon, L. B., Holoshitz, Y., & Nossel, I. (2016). Treatment engagement of individuals  
experiencing mental illness: Review and update. World Psychiatry, 15(1), 13-20.  
Drake, R. E., O’Neil, E. L., & Wallach, M. A. (2012). A systematic review of psychosocial  
research on psychosocial interventions for people with co-occurring severe mental 
and substance misuse disorders. Journal of Substance Abuse Treatment, 24, 123-138.  
Gobbart, S. (2013). ‘Changing habits’: An evaluation of a dual diagnosis focused, integrated,  
multimodal, psychosocial education and skill building group programme delivered in 
a community-based setting. Mental Health and Substance Use, 6(1), 29-46. 
doi:10.1080/17523281.2012.660980 
Gray, C. D., & Kinnear, P. R. (2012). IBM statistics 19 Made Simple. New York: Psychology  
Press. 
Jackson, C. T., Covell, N. H., Drake, R. E., & Essock, S. M. (2007). Relationship between  
diabetes and mortality among persons with co-occurring psychotic and substance use 
disorders. Psychiatric Services, 58(2), 270-272.  
Jackson, K. M., Sher, K. J., & Schulenberg, J. E. (2008). Conjoint development trajectories of  
young adult substance use. Clinical and Experimental Research, 32, 723-737.  
  
Psychoeducational therapy in dual diagnosis 
21 
 
Lukoff, D., Liberman, R. P., & Nuechterlein, K. H. (1986). Symptom monitoring in the  
rehabilitation of schizophrenic patients. Schizophrenia Bulletin, 12(4), 578-602. 
doi:10.1093/schbul/12.4.578 
Manning, V., Betteridge, S., Wanigaratne, S., Best, D., Strang, J., & Gossop, M. (2009).  
Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use 
disorder. Schizophrenia Research, 114(1), 98-104.  
Miller, W. R., & Tonigan, J. S. (1996). Assessing drinker’s motivation for change: The States  
of Change Readiness and Treatment Eagerness scale (SOCRATES). Psychology of 
Additive Behaviours, 10, 81-89.  
Minkoff, K. & Cline, C.A. (2005). Developing Welcoming Systems for Individuals with Co-
Occurring Disorders: The role of the Comprehensive Continuous Integrated System 
of Care Model. Journal of Dual Diagnosis, 1(1), 65-89.  
Minkoff, K. (2013). Treating comorbid psychiatric and substance use disorders. Psychiatric  
Times, 30(4), 13-13.  
Morgan, S., & Carson, J. (2009). The Recovery Group: A service user and professional  
perspective. Group-work, 19, 26-39.  
NICE. (2011a). Psychosis with co-existing substance misuse: Assessment and management in  
adults and young people. London: National Institute for Health and Clinical 
Excellence. 
NICE. (2011b). Schizophrenia; core interventions in the treatment and management of  
schizophrenia in adults in primary and secondary care. London: National Institute for 
Health and Clinical Excellence. 
NICE. (2014). Psychosis and schizophrenia in adults: Treatment and management. London:  
National Institute for Health and Clinical Excellence. 
  
Psychoeducational therapy in dual diagnosis 
22 
 
NICE. (2016). Coexisting severe mental illness and substance misuse: Community health and  
social care services. London: National Institute for Health and Clinical Excellence. 
Nutt, D., King, L., & Nichols, D. (2013). Effects of schedule 1 drug laws on neuroscience  
research and treatment innovation. Nature Reviews Neuroscience, 14, 577-585.  
Overall, J. E., & Gorham, D. R. (1962). The Brief Psychiatric Rating scale. Psychological  
Reports, 10, 799-812. doi:10.2466/pr0.1962.10.3.799 
Sibitz, I., Amering, M., Gössler, R., Unger, A., & Katschnig, H. (2007). Patients' perspectives  
on what works in psychoeducational groups for schizophrenia: A qualitative study. 
Social Psychiatry and Psychiatric Epidemiology, 42(11), 909-915. 
doi:10.1007/s00127-007-0245-5 
Tay, D. (2011). Therapy is a journey as a discourse metaphor. Discourse Studies, 13, 47-68.  
Tennant, R., Hiller, L., Fishwick, R., Platt, S., Joseph, S., Weich, S., & Stewart-Brown, S.  
(2007). The Warwick-Edinburgh Mental Well-Being scale (WEMWBS): 
Development and UK validation. Health and Quality of Life Outcomes, 5, 63.  
Ujhelyi, K., Ujhelyi, K., Carson, J., Carson, J., Holland, M., & Holland, M. (2016). Positive  
psychology in dual diagnosis: A preliminary investigation. Advances in Dual 
Diagnosis, 9(4), 139-153.  
Ventura, J., Nuechterlein, K. H., Subotnik, K. L., Gutkind, D., & Gilbert, E. A. (2000).  
Symptom dimensions in recent-onset schizophrenia and mania: A principal 
components analysis of the 24-item Brief Psychiatric Rating scale. Psychiatry 
Research, 97, 129-135. doi:10.1016/S0165-1781(00)00228-6 
Weiss, R. D., Griffin, M. L., Kolodziej, M. E., Greenfield, S. F., Najavits, L. M., Daley, D. 
C., ... Hennen, J. A. (2007). A randomized trial of integrated group therapy versus 
group drug counseling for patients with bipolar disorder and substance dependence. 
American Journal of Psychiatry, 164(1), 100-107.  
Psychoeducational therapy in dual diagnosis 
23 
 
Wertshc, J. (1986). Culture, communication, and cognition: Vygotskian perspectives.  
Cambridge: Cambridge University Press. 
Zammit, S., Moore, T. H., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., &  
Lewis, G. (2008). Effects of cannabis use on outcomes of psychotic disorders: 
Systematic review. The British Journal of Psychiatry, 193 (5), 357-363.  
Zigmond, A. S., & Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. Acta  
Psychiatric Scandinavica, 67, 361-370.  
